New Science

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.

Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech. 

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

According to China Pharmaceutical Innovation and Research Development Association, in the first quarter of 2024 a total of 44 cell therapies in the domestic cell therapy field made clinical application progress, including 28 immune cell therapies and 16 stem cell therapies.

Citeline analysts offered deep dives into some of the data presented at the American Society of Clinical Oncology annual meeting, including both major highlights and some lesser-known finds. 

Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Computing, including AI, applied to life sciences is undeniably a rapidly growing area, driven by significant investment, recent technological advancements and heightened public interest. A look at published patents from 2014 to 2023 reveals trends in patent filings across various life sciences sectors and highlights geographical hotspots.

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.

Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.